Obeticholic Acid

For research use only. Not for use in humans.

製品コードS7660 別名:INT-747, 6-ECDCA, 6-Ethylchenodeoxycholic acid

Obeticholic Acid化学構造

CAS No. 459789-99-2

Obeticholic Acid (INT-747, 6-ECDCA, 6-Ethylchenodeoxycholic acid) is a potent and selective farnesoid X receptor (FXR) agonist with EC50 of 99 nM. Obeticholic Acid inhibits autophagy. Phase 3.

サイズ 価格(税別)  
JPY 18100
JPY 59600
JPY 164100
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

カスタマーフィードバック(3)

  • (c) Functional bile canaliculi or lack thereof in PHHs within MPTCs (12 d of drug treatment) as visualized by transport of fluorescent (green) dye into the canaliculi between PHHs. DMSO-treated MPCC control image is shown to the far right. (d) Neutral lipid (Nile red, green) staining of PHHs within MPTCs (12 d of drug treatment). DMSO-treated MPCC control image is shown to the far right. (e) NR1I2 (PXR) gene expression in drug-treated MPTCs relative to DMSOtreated MPTC controls (12 d of treatment). (f) ABCC2 (MRP2) gene expression in drug-treated MPTCs relative to DMSO-treated MPTC controls (12 d of treatment). (g) IL-6 levels in drug-treated MPTC supernatants (6 d of treatment). In all panels, statistical significance is displayed relative to DMSO-treated MPTCs. *p r 0.05, **p r 0.01, ***p r 0.001, and ****p r 0.0001. Scale bars on images represent 80 mm.

    Integr Biol (Camb), 2017, 9(8):662-677. Obeticholic Acid purchased from Selleck.

  • HuCCT1 cells were treated with OCA (1 μM) and control solvent in the presence and absence of IL-6 (20 ng/mL). EMT-related proteins were examined by western blotting. β-actin was used as a control.

    Cell Physiol Biochem, 2018, 48(1):158-172. Obeticholic Acid purchased from Selleck.

  • (D) Expression of hepatic FXR target genes, n = 3. Data are expressed as mean ± SD, ###P < 0.001 versus group 1, *P < 0.05, **P < 0.01, and ***P b 0.001 versus group 2, sP < 0.05, ssP < 0.01, and sssP < 0.001 versus group 3

    Toxicol Appl Pharmacol, 2017, 315:23-34. Obeticholic Acid purchased from Selleck.

質量管理及び製品安全説明書

FXR阻害剤の選択性比較

生物活性

製品説明 Obeticholic Acid (INT-747, 6-ECDCA, 6-Ethylchenodeoxycholic acid) is a potent and selective farnesoid X receptor (FXR) agonist with EC50 of 99 nM. Obeticholic Acid inhibits autophagy. Phase 3.
ターゲット
FXR [1]
99 nM(EC50)
体外試験

In HuH7 cells, Obeticholic Acid acts as a potent FXR agonist with EC50 of 85 nM. [1]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
insect cells MXnGeY5kfGmxbjDhd5NigQ>? NF3SWYIyKGi{ NYjtXFV2SWexbnnzeEBi[3Srdnn0fUBifCC{ZXPvcYJqdmGwdDDoeY1idiCJU2SteIFo\2WmIF\YVkBtcWejbnSgZolv\GmwZzDkc41icW5iKEG5N{B1dyB2N{KgdoV{cWS3ZYOpJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiY3XscJMh[XO|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJIlvfGW{YXP0bY9vKHerdHigZolwfGmwIHzhZoVtdGWmIGPSR{0yKGGodHXyJFEhcHJiYomgTHRTTiCjc4PhfUwhTUN3MDC9JFAvODFizszNMi=> M{XNd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUS4PFA3Lz5{OUG0PFgxPjxxYU6=
HEK293T NYfIWVNSTnWwY4Tpc44h[XO|YYm= NYD5Ood1OjRiaILz MYHB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIF\YVkBmgHC{ZYPz[YQhcW5iSFXLNlk{XCClZXzsd{Bie3Onc4Pl[EBieyCEU1XQJJBzd22xdHXyJIRzcX[nbjDj[YxtfWyjcjD0doFve2O{aYD0bY9v[WxiYXP0bZZqfHliYX\0[ZIhOjRiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OCB;IECuNFQzKM7:TT6= MmrIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzNEi4NFYoRjJ7MUS4PFA3RC:jPh?=
COS1 MljHSpVv[3Srb36gZZN{[Xl? NX3vXZg1SWexbnnzeEBi[3Srdnn0fUBifCCIWGKg[ZhxemW|c3XkJIlvKEORU{GgZ4VtdHNiYomgZ4VtdC2kYYPl[EBjcW:udX3pcoV{[2WwY3WgZZN{[XluIFXDOVAhRSByLkC5PUDPxE1w M2D5bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEG0PFcxLz5{MECxOFg4ODxxYU6=
HeLa NWHMdZVUTnWwY4Tpc44h[XO|YYm= NFTvOZUzPCCqcoO= MWfB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIH\1cIwhdGWwZ4ToJGZZWiCneIDy[ZN{\WRiaX6gTIVN[SClZXzsd{Bkd3S{YX7z[oVkfGWmIIfpeIgheFOJNT3oeY1idiCUWGKgZYZ1\XJiMkSgbJJ{KGK7IFT1ZYwuT2yxIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3MDC9JFAvOTZizszNMi=> Mo\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7M{SyNlcoRjJ3OUO0NlI4RC:jPh?=
HeLa Mnj0SpVv[3Srb36gZZN{[Xl? M{fVNGFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gSnhTKGW6cILld5Nm\CCrbjDoeY1idiCKZVzhJINmdGy|IHHzd4V{e2WmIHHzJJJm[2WydH;yJIFkfGm4YYTpc44h[nliQmPFVEBxem:vb4Tldk1lemm4ZX6g[olz\W[ueTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUCgQUAxNjF4IN88UU4> MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ3NUCzPUc,OjV{NUWwN|k9N2F-
insect cells MmPFSpVv[3Srb36gZZN{[Xl? MVOxJIhz M2XVPGFod26rc4SgZYN1cX[rdImgZZQhemWlb33ibY5idnRiaIXtZY4hT1OWLYTh[4dm\CCIWGKgUGJFKChzOUOgeI8hPDd{IILld4llfWW|KTDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiaX7z[YN1KGOnbHzzJIF{e2W|c3XkJIF{KHKnY4L1bZRu\W62IH;mJIJqd3SrbonsZZRm\CCVUlOxJJBmeHSrZHWgcYVie3W{ZXSgZYZ1\XJiMTDodkBjgSCDbIDoZZNkemWnbjDhd5NigSxiRVO1NEA:KDBwMUig{txONg>? MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ3OUe0Nkc,Ojl{NUm3OFI9N2F-
COS1 MXvGeY5kfGmxbjDhd5NigQ>? M1jNZlUhcHK| NHnoPFRC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJGZZWiCneIDy[ZN{\WRiaX6gR29UOSClZXzsd{Bi\nSncjC1JIhzeyCkeTDDVmUu\HKrdnXuJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDBwM{[xJO69VS5? MmHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4OEW2NFMoRjF5Nki1OlA{RC:jPh?=
CHO MUPGeY5kfGmxbjDhd5NigQ>? MUK1JIhzew>? M{D1TmFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gWGdTPSCneIDy[ZN{\WRiaX6gR2hQKGOnbHzzJIFnfGW{IEWgbJJ{KGK7IFPSSU1lemm4ZX6gcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwJF0hOC55NUWg{txONg>? NVPHfW54RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2PFU3ODNpPkG3Olg2PjB|PD;hQi=>
HEK293 MUHGeY5kfGmxbjDhd5NigQ>? M4H4elEhcHJ? MlvORYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDUS3I2KGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbY51emGlZXzseYxieiClQV3QJIxmfmWuIHHmeIVzKDFiaIKgZpkhXFJvRmLFWEBie3OjeTygSWM2OCB;IECuPFQh|ryPLh?= MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ3OUe0Nkc,Ojl{NUm3OFI9N2F-
NCI-H716 NEDGVFRHfW6ldHnvckBie3OjeR?= MVTB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGTHVlUhemWlZYD0c5Ih\XiycnXzd4VlKGmwIF7DTU1JPzF4IHPlcIx{KGG|c3Xzd4VlKGG|IHnueJJi[2WubIXsZZIh[0GPUDDs[ZZmdCCkeTDUVk1HWkWWIHHzd4F6NCCHQ{WwJF0hOjBizszNMi=> NIjYVoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS1PVU5OCd-MkG0OVk2QDB:L3G+
HepG2 M1n3R2Z2dmO2aX;uJIF{e2G7 M{jielIxKHWP M{n6TWlv\HWldHnvckBw\iCIWGKtcYVlcWG2ZXSgV2hRKG2UTlGg[ZhxemW|c3nvckBqdiCqdX3hckBJ\XCJMjDj[YxteyCjdDCyNEB2VSCkeTDSWE1RS1J? NUHZN2FERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OVk2QDBpPkKxOFU6PThyPD;hQi=>
HepG2 M13NTmZ2dmO2aX;uJIF{e2G7 M4jBVVEhfU1? NYXFcYNPUW6mdXP0bY9vKG:oIF\YVk1u\WSrYYTl[EBUUFBibWLORUBmgHC{ZYPzbY9vKGmwIHj1cYFvKEincFeyJINmdGy|IHH0JFEhfU1iYomgVnQuWEOU MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR3OUW4NEc,OjF2NUm1PFA9N2F-
HepG2 M1LzW2Z2dmO2aX;uJIF{e2G7 M13nOVIxKHWP NGL5dlJKdmS3Y4Tpc44hd2ZiRmjSMY1m\GmjdHXkJGJUTVBibWLORUBmgHC{ZYPzbY9vKGmwIHj1cYFvKEincFeyJINmdGy|IHH0JFIxKHWPIHL5JHJVNVCFUh?= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR3OUW4NEc,OjF2NUm1PFA9N2F-
HepG2 NHXiVXBHfW6ldHnvckBie3OjeR?= M3HJUlIxKHWP NF7OTJZKdmS3Y4Tpc44hd2ZiRmjSMY1m\GmjdHXkJG9{fGKndHGgcXJPSSCneIDy[ZN{cW:wIHnuJIh2dWGwIFjldGczKGOnbHzzJIF1KDJyIIXNJIJ6KFKWLWDDVi=> MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR3OUW4NEc,OjF2NUm1PFA9N2F-
HepG2 MYTGeY5kfGmxbjDhd5NigQ>? NUfxO5dHOSC3TR?= MWTJcoR2[3Srb36gc4YhTliULX3l[IlifGWmIHTve44uemWpdXzheIlwdiCxZjDDfZA4STFibWLORUBmgHC{ZYPzbY9vKGmwIHj1cYFvKEincFeyJINmdGy|IHH0JFEhfU1iYomgVnQuWEOU M4\IRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW5OVgxLz5{MUS1PVU5ODxxYU6=
HepG2 NGC5Z4JHfW6ldHnvckBie3OjeR?= MmiwNlAhfU1? NYftVodlUW6mdXP0bY9vKG:oIF\YVk1u\WSrYYTl[EBld3ewLYLl[5Vt[XSrb36gc4YhS3myN1GxJI1TVkFiZYjwdoV{e2mxbjDpckBpfW2jbjDI[ZBIOiClZXzsd{BifCB{MDD1UUBjgSCUVD3QR3I> NHvGe409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS1PVU5OCd-MkG0OVk2QDB:L3G+
HepG2 MUnGeY5kfGmxbjDhd5NigQ>? NWjwenNROjBidV2= M2fqN2Fod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gSnhTKGW6cILld5Nm\CCrbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyC{ZX7pcIxiKGy3Y3nm[ZJie2ViYXP0bZZqfHliYYSgNlAhfU1iYomgcJVkcW[ncnHz[UBj[XOnZDD0doFve2GldHn2ZZRqd25iYYPzZZk> Ml7OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NUm1PFAoRjJzNEW5OVgxRC:jPh?=
HepG2 M1HHPWZ2dmO2aX;uJIF{e2G7 M{K0RlEhfU1? M1LMe2lv\HWldHnvckBw\iCIWGKtcYVlcWG2ZXSgRnNGWCCvUl7BJIV5eHKnc4Ppc44hcW5iaIXtZY4hUGWyR{KgZ4VtdHNiYYSgNUB2VSCkeTDSWE1RS1J? MlvBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NUm1PFAoRjJzNEW5OVgxRC:jPh?=
HepG2 M1TnWmZ2dmO2aX;uJIF{e2G7 NGDvelkyKHWP MXzJcoR2[3Srb36gc4YhTliULX3l[IlifGWmIF;zeIJmfGFibWLORUBmgHC{ZYPzbY9vKGmwIHj1cYFvKEincFeyJINmdGy|IHH0JFEhfU1iYomgVnQuWEOU NFjZN3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS1PVU5OCd-MkG0OVk2QDB:L3G+
HepG2 NUTjepUzTnWwY4Tpc44h[XO|YYm= NFXo[pYyOCC3TR?= NIXpdZJVemGwc3HjeIl3[XSrb36gc4YhcHWvYX6gSnhTKHS{YX7z[oVkfGWmIHnuJIh2dWGwIFjldGczKGOnbHzzJIF1KDFyIIXNJIJ6KGKndHGt[4Ft[WO2b4Pp[IF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7 NYfkS2VJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPFc{OjVpPkK0N|g4OzJ3PD;hQi=>
HepG2 NUHzdHVLTnWwY4Tpc44h[XO|YYm= M4jmbFExKHWP NUHLOJFtOThiaILz NIrtNoxC\2:waYP0JIFkfGm4aYT5JIF1KE[[UjDpckBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyC3cILl[5Vt[XSrb36gc4YhV1OWLXHsdIhiKG2UTlGg[ZhxemW|c3nvckBifCBzMDD1UUBi\nSncjCxPEBpenNiYomgVnQuWEOUIHHuZYx6e2m| NV3pcFNvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPFc{OjVpPkK0N|g4OzJ3PD;hQi=>
GLUTag NInqe|BHfW6ldHnvckBie3OjeR?= NXKyPHFbSWexbnnzeEBi[3Srdnn0fUBifCCJUD3CRXIyKGmwIH3veZNmKEeOVWTh[{Bk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCrboTyZYNmdGy3bHHyJINCVVBibHX2[Yw> NEXuZ5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO4O|MzPSd-MkSzPFc{OjV:L3G+
HepG2 MWrGeY5kfGmxbjDhd5NigQ>? NUXxZZNlOTBidV2= M4DDflE5KGi{cx?= MULB[49vcXO2IHHjeIl3cXS7IHH0JGZZWiCrbjDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{B2eHKnZ4XsZZRqd25ib3[gV2hRKG2UTlGg[ZhxemW|c3nvckBifCBzMDD1UUBi\nSncjCxPEBpenNiYomgVnQuWEOUIHHuZYx6e2m| M{TxdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{i3N|I2Lz5{NEO4O|MzPTxxYU6=
HepG2 MoX6SpVv[3Srb36gZZN{[Xl? MVKxNEB2VQ>? NX\zUFY3OThiaILz M1fGTWFod26rc4SgZYN1cX[rdImgZZQhTliUIHnuJIh2dWGwIFjldGczKGOnbHzzJIF{e2W|c3XkJIF{KHWycnXneYxifGmxbjDv[kBDTVOSIH3SUmEh\XiycnXzd4lwdiCjdDCxNEB2VSCjZoTldkAyQCCqcoOgZpkhWlRvUFPSJIFv[Wy7c3nz MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN6N{OyOUc,OjR|OEezNlU9N2F-
GLUTag NFG2bohHfW6ldHnvckBie3OjeR?= NEW4WI1C\2:waYP0JIFkfGm4aYT5JIF1KEeSLVLBVlEhcW5ibX;1d4UhT0yXVHHnJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKEeOUD2xJJJmdGWjc3W= NX\Ve3U1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPFc{OjVpPkK0N|g4OzJ3PD;hQi=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
XBP1s; 

PubMed: 29377207     


Huh7-Ntcp cells were treated with 6-ECDCA (0-10 μM) or DMSO vehicle for 4 hours. Representative western blot of XBP1s is shown with GAPDH used as a loading control.

p-IRE1α; 

PubMed: 29377207     


Huh7-Ntcp cells were treated with 2.5 μM 6-ECDCA or DMSO for 2 hours. Western blotting was performed for phosphorylated-IRE1α (p-IRE1α). Cellular p-IRE1α expression is increased in Huh7-Ntcp cells in response to FXR-agonist treatment.

29377207
体内試験 In rat cholestasis model, Obeticholic Acid promotes bile flow, and protects hepatocytes against acute necrosis caused by LCA. [1] Obeticholic Acid (p.o.) improves proteinuria, ameliorates renal structural changes, and modulates renal inflammation and oxidative stress in WD-fed DBA mice. [2] In thioacetamide (TAA)-intoxicated and bile-duct-ligated (BDL) rats, Obeticholic Acid (30 mg/kg p.o.) reactivates the FXR downstream signaling pathway and decreases portal pressure by lowering total IHVR without deleterious systemic hypotension. [3]

お薦めの試験操作(参考用のみ)

動物試験:

[1]

- 合併
  • 動物モデル: Rat cholestasis model
  • 投薬量: Saline
  • 投与方法: Infused at the right jugular vein using PE-50 polyethylene tubing
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.7 mM)
Water Insoluble
Ethanol ''84 mg/mL warmed ''84

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 420.63
化学式

C26H44O4

CAS No. 459789-99-2
Storage powder
in solvent
別名 INT-747, 6-ECDCA, 6-Ethylchenodeoxycholic acid
Smiles CCC1C2CC(CCC2(C3CCC4(C(C3C1O)CCC4C(C)CCC(=O)O)C)C)O

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02633956 Completed Drug: Obeticholic Acid|Drug: Atorvastatin|Drug: Placebo Nonalcoholic Steatohepatitis Intercept Pharmaceuticals December 4 2015 Phase 2
NCT02548351 Active not recruiting Drug: Obeticholic Acid|Drug: Placebo Non Alcoholic Steatohepatitis (NASH) Intercept Pharmaceuticals September 22 2015 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    What formulation can we use to dissolve Obeticholic Acid (Catalog No.S7660) for mice in vivo study?

  • 回答:

    You can use the vehicle of: 1% wt/vol methyl-cellulose as indicated in this paper, http://www.sciencedirect.com/science/article/pii/S0925443911000883 "daily oral gavage with 5 mg/kg/day INT-747 (6-ethyl-chenodeoxycholic acid, Obeticholic acid, Intercept Pharmaceuticals Inc, New York, NY) or vehicle (1% wt/vol methyl-cellulose) from 3 days prior to induction of colitis"

相関FXR製品

Tags: Obeticholic Acidを買う | Obeticholic Acid ic50 | Obeticholic Acid供給者 | Obeticholic Acidを購入する | Obeticholic Acid費用 | Obeticholic Acid生産者 | オーダーObeticholic Acid | Obeticholic Acid化学構造 | Obeticholic Acid分子量 | Obeticholic Acid代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID